Cytokine Design via Computational Residue Mutation

The patent applies parameter changes by systematically varying amino acid residues at specific positions in the cytokine sequence. The computational algorithms evaluate multiple sequence variants by changing parameters such as hydrophobicity, charge, and steric properties at targeted positions to optimize thermal stability while managing design complexity through focused residue selection.

The patent employs preliminary action through in silico screening and evaluation of potential mutations before experimental implementation. The computational redesign algorithms predict stability improvements for candidate variants, allowing the most promising designs to be selected for synthesis and testing, thereby reducing the complexity of the overall design process.

The patent applies local quality by making targeted mutations at specific residues involved in receptor binding interfaces rather than global sequence changes. This allows alteration of binding selectivity for particular cognate receptors while preserving the overall cytokine structure and general functionality, thereby improving specificity without compromising reliability.

The patent employs feedback mechanisms where computational algorithms evaluate the predicted impact of mutations on both binding selectivity and functional stability. The design process iteratively refines variants based on predicted outcomes, allowing optimization of receptor specificity while monitoring and maintaining functional reliability through computational assessment.

The patent applies preliminary action through in silico validation and computational screening of mutations before experimental implementation. The algorithms predict which mutations are most likely to succeed based on structural and energetic criteria, allowing the research team to focus experimental resources on the most promising variants and thereby maintain high manufacturing precision without excessive productivity loss.

The patent employs partial action by implementing a tiered screening approach where not all possible mutations are validated experimentally. Instead, computational methods prioritize and filter variants, and only the most promising candidates undergo extensive experimental validation, balancing manufacturing precision with productivity by applying full screening rigor only where necessary.